Summary
• Revelation Biosciences, Inc. (REVB) fell 5.1% in after-hours trading, pricing at $0.905.
• The company is set for a special shareholder meeting on December 3, 2025, following quorum confirmation.
• Recent updates include nearing an end-of-phase 1 meeting with the FDA regarding treatment for acute kidney injury (AKI).
Revelation Biosciences, Inc. (NASDAQ: REVB) experienced a decline of 5.1% in after-hours trading, pricing at $0.905 compared to its last close of $0.9533. This downward movement occurred without a defined catalyst.
Corporate Governance Update
On December 1, 2025, Revelation Biosciences announced it had successfully reached a quorum for its special meeting scheduled for December 3, 2025. Shareholders are reminded that voting is open until 11:59 PM ET on December 2, 2025. Although this announcement provides operational context, it did not have a notable impact on current trading dynamics.
Recent Developments and Momentum
Earlier in November, the company confirmed it is on track for an end-of-phase 1 meeting with the FDA, with plans to discuss the clinical development pathway for its treatment targeting acute kidney injury (AKI). The successful submission and acceptance of the meeting package is a significant milestone for the firm as it seeks input from regulatory authorities for further advancements.
Regulatory Filings and Disclosures
As of late November 2025, there are no new SEC filings tied to the company that would represent a change in hypothesis or strategy from what is already known. The focus remains on the upcoming special meeting scheduled for December 3, which primarily serves procedural purposes at this time.
Market and Technical Picture
The stock’s 10-day average volume stands at 69,424 shares, which is significantly lower than its 3-month average of 393,263, highlighting a decrease in trading activity. Revelation Biosciences has seen a sharp decline over the past year, with a 97.4% drop in share value. The stock’s 14-day RSI is currently at 38.76, indicating it sits in a relatively neutral position, while it approaches the lower end of its trading range within the past 52 weeks.
As this after-hours move reflects routine trading conditions, investors will be watching closely to assess how Revelation’s stock performance responds to its operational updates and special meeting outcomes in the sessions to come.